Healthcare Practice Valuation Calculator: 2026 EBITDA Multiples, Escrow and Cash at Close
A healthcare practice sells for adjusted EBITDA times a multiple. The seller then receives equity value less escrow, earnout and rollover. For 2026, FOCUS Investment Banking's dashboard gives 8.8x for multi-specialty practices with $5 to $10 million of EBITDA, a single published benchmark figure. Its dermatology benchmarks run from 3x to 5x for solo practices under $2 million of revenue up to 12x to 15x for platforms above $50 million. SRS Acquiom's 2025 deals across all sectors had a median total escrow of 11.1% of transaction value without RWI and 2.8% with it. Enter adjusted EBITDA and a multiple range below. The calculator returns enterprise and equity value, and the tables carry it to cash at close.
Estimate only. Educational, not investment advice.
Data as of November 20, 2026. Sources: FOCUS Investment Banking (2026 dashboard and 2026 dermatology benchmarks, published benchmark figures with no stated sample), Aswath Damodaran at NYU Stern (US listed companies, January 2026), SRS Acquiom (2025 deals, all sectors), PESP via Becker's ASC Review (2025 outpatient deals), Kaufman Hall via Becker's Hospital Review (hospital announcements through Q3 2026) and CMS (2024 national health spending). Every worked example uses invented inputs, and every derived figure is our arithmetic.
What the Calculator Counts, and What It Leaves to You
Inputs
| Input | What to enter | How the tool uses it |
|---|---|---|
| Revenue and reported EBITDA margin | Trailing 12 months, the same period the buyer uses. Enter the margin exactly as reported, with no adjustments. | Reported EBITDA = revenue x margin |
| One-time costs to add back | Documented, non-recurring costs inside reported EBITDA, such as a one-off legal bill | Added to reported EBITDA once |
| Number of owners | Physicians or partners drawing owner pay | Sets how many market salaries to deduct |
| Total owner pay | Owner salary and bonus expensed in the P&L above the EBITDA line. Leave out distributions. | Starting point for the owner-pay add-back |
| Market replacement pay per owner | What the buyer must pay a physician to do each owner's job | Add-back = total owner pay minus (owners x market pay). Negative if owners are underpaid. |
| Rent adjustment: plus if above market, minus if below market | Positive if the practice pays an owner-landlord above market rent. Negative if rent is below market. | Added to EBITDA as entered |
| Low and high multiple | Band chosen with the selection table below, or a buyer's written quote | EV = adjusted EBITDA x each multiple |
| Net debt | Debt repaid at closing less cash the seller keeps, as your agreement defines both | Equity value = EV minus net debt |
Three rules to stop double counting:
- Distributions are not add-backs. Profit distributed to owners below the EBITDA line is already inside reported EBITDA. Enter only pay that is expensed in the P&L.
- One-time costs go in their own field only. Enter the reported margin unadjusted. Example: a practice with $6,000,000 of revenue reports a 15% margin, $900,000 of EBITDA, after a $40,000 one-off legal bill. Enter 15% and $40,000. Entering a 15.67% margin and $40,000 counts the bill twice (our arithmetic).
- One adjustment per item. If your accountant already normalized owner pay or rent in the reported figures, enter zero for that adjustment here.
Outputs: adjusted EBITDA, an enterprise value (EV) range and an equity value range. Equity value comes before escrow, earnout, rollover, any working capital adjustment, fees and taxes. It is not cash.
Not calculated here:
| Item | Formula on this page | What the number means |
|---|---|---|
| Escrow | Escrow rate x the base named in your agreement | Deferred cash, released later if no claims are made |
| Earnout, expected value | Earnout amount x your own probability estimate | Undiscounted scenario math, not a present value |
| Rollover equity | Amount rolled into the buyer's entity | Illiquid, carried at cost, no cash at close |
| Fees and taxes | Your engagement letters and tax position | Carry equity value to the Deal Proceeds Calculator |
Enter only add-backs you can document. A rejected add-back is lost at the full multiple.
Setting market pay. The market pay you enter is also what the buyer must pay each physician after closing, so set it the way the buyer will. Use specialty compensation surveys for your region, and check them against official wage data on the BLS Health Care and Social Assistance industry page. Setting market pay too low inflates the add-back, and the buyer's quality of earnings team will reverse it.
Set the Multiple: Size, Specialty, Owner Dependence, Payer Mix and Buyer Type
The calculator takes a low and a high multiple. Five factors decide where they sit. Place size first.
Why size comes first (our reading of FOCUS's 2026 figures). In FOCUS's $5 to $10 million EBITDA column, the provider rows run from 8.8x for multi-specialty practices to 11.3x for plastic surgery, a 2.5-turn spread across specialties at one size. In FOCUS's dermatology table, one step from the small-group band (4x to 7x, midpoint 5.5x) to the regional band (8x to 10x, midpoint 9x) moves the midpoint 3.5 turns (our arithmetic). The two tables sort by different measures (EBITDA in one, revenue in the other), so this is not a controlled comparison. It still shows that a single size step can move the multiple further than the whole specialty spread.
| Factor | What the 2026 data shows | How to set your inputs |
|---|---|---|
| 1. Size | Dermatology multiples rise from 3x to 5x (solo, under $2M revenue) to 12x to 15x ($50M+ revenue or $10M+ EBITDA) (FOCUS dermatology, 2026). FOCUS also reports that healthcare companies above $10M of revenue "often see a 1.5x to 2x jump in valuation multiples" (FOCUS dashboard, 2026). | Place your practice by size before anything else. Below $5M of EBITDA, treat FOCUS's 8.8x multi-specialty figure as an upper reference. That cap is our judgment, not a FOCUS figure. |
| 2. Specialty | Dermatology has a four-band scale. Multi-specialty practices, plastic surgery and hospitals have one figure each, at $5M to $10M of EBITDA. | Use the specialty row if one exists. If not, follow the method for unpublished specialties below. |
| 3. Owner dependence | FOCUS describes solo dermatology practices as "owner-dependent" and prices them at 3x to 5x, against 4x to 7x for small groups. | If one physician produces most collections with no signed plan to stay, set the low case one band down. |
| 4. Payer mix | Buyers favor practices with more than 70% commercial or cash-pay revenue for revenue quality, faster collections and protection from government reimbursement cuts (FOCUS dermatology, 2026). | Above 70% supports the top half of your band. A Medicare- or Medicaid-heavy book supports the bottom half. FOCUS publishes no numeric premium, so stay inside the band. |
| 5. Buyer type | Corporate buyers in therapeutic and technology-driven sectors paid 20% to 40% higher multiples than financial sponsors on like-for-like EBITDA (FOCUS dashboard, 2026). | Model a sponsor case. Add a strategic case at 1.2x to 1.4x the sponsor multiple only if a strategic buyer is in the process. FOCUS measured the premium in those sectors, so applying it to a practice is our assumption. |
Why payer mix carries weight. In the CMS National Health Expenditure fact sheet, private health insurance spending was $1,644.6 billion in 2024, 31% of US health spending, and Medicare spending grew 7.8% to $1,118.0 billion, 21% of the total. Commercial rates are negotiated with each plan. Government rates are set by the payer. A buyer underwriting five years of EBITDA prices that difference.
Worked example, buyer type (our arithmetic, our assumption that FOCUS's sector premium carries over). A sponsor prices a practice at 5.0x. Applying FOCUS's 20% to 40% range gives a strategic case of 5.0 x 1.2 = 6.0x to 5.0 x 1.4 = 7.0x. On $1,200,000 of adjusted EBITDA, EV moves from $6,000,000 to between $7,200,000 and $8,400,000.
Worked example, the $10 million revenue line (our arithmetic). FOCUS does not say whether its 1.5x to 2x jump multiplies the multiple or adds turns. On a 4x starting multiple, the multiplier reading gives 6x to 8x and the turns reading gives 5.5x to 6x. FOCUS says "often," and buyers price infrastructure and margin consistency, not a revenue figure. Model the lower reading and treat the jump as a gradient across the $10 million line, not a step at it.
Specialty reference points, 2026
| Specialty | Published multiple and source | 2025 outpatient deal count (PESP via Becker's ASC Review) | What to enter |
|---|---|---|---|
| Dermatology | 3x to 15x across four revenue bands (FOCUS dermatology, 2026) | 24, the most of any outpatient subsector | The band from the dermatology table below |
| Eye care and ophthalmology | No band in FOCUS's 2026 pages | 22 | Unpublished-specialty method below |
| Oncology | No band in FOCUS's 2026 pages | 9 | Unpublished-specialty method below |
| Orthopedics, GI, dental | No band in FOCUS's 2026 pages | Not among the top three subsectors reported | Unpublished-specialty method below |
| Ambulatory surgery centers | No band in FOCUS's 2026 pages | Not broken out | Unpublished-specialty method below |
| Multi-specialty practices | 8.8x at $5M to $10M EBITDA, single benchmark figure (FOCUS dashboard, 2026) | Not broken out | 8.8x as the high case at that size |
| Plastic surgery | 11.3x at $5M to $10M EBITDA, "highest variance" (FOCUS dashboard, 2026) | Not broken out | A wide range, because elective demand moves with the economy |
| Hospitals | 9.7x at $5M to $10M EBITDA (FOCUS dashboard, 2026) | Hospitals tracked separately below | The FOCUS figure at that size |
Method for a specialty with no published band. Eye care, orthopedics, GI, dental and ASCs are active buyer markets, and none has a 2026 band in the sources used here. Do not borrow dermatology's scale. Instead:
- Start from FOCUS's 8.8x multi-specialty figure if your EBITDA is $5 to $10 million. Below that, set your high case under 8.8x (our judgment, as above).
- Move within that range on owner dependence and payer mix, using the factor table.
- Replace both inputs with buyers' written multiples as soon as you have them, and ask each buyer to state the multiple and the accepted EBITDA as two separate numbers.
Of the 148 outpatient care deals PESP counted in 2025, 119 were add-on acquisitions (Becker's ASC Review). For most practices, the realistic buyer is an existing platform adding a location. Model that buyer first.
From Benchmarks to Evidence: Replace Published Ranges With Written Bids
FOCUS's figures are banker-published benchmarks with no stated sample size. Damodaran's figures are listed-company multiples. Neither is a closed-deal median for practices like yours. Use them to set a starting range, then replace them with evidence from your own process.
| Evidence | What to ask for | Why it beats a benchmark |
|---|---|---|
| Written indications of interest | Multiple and accepted adjusted EBITDA as two separate numbers | Shows whether a gap is about price or about which add-backs the buyer accepts |
| Structure terms in each bid | Cash at close as a share of price, escrow rate and base, earnout size and metric, rollover share | Two bids can differ by hundreds of thousands at close, as the two-offer table below shows |
| Buyer's recent comparable closings | Date, size band and structure of practices the buyer has bought | A buyer's own closings are the closest closed-deal data you can get |
| Comparable sales quoted by peers | Date, sample, cash at close and deferred share | Last year's headline multiple may predate the drop in the public median (below) |
| Adviser background | The firm's and banker's record on FINRA BrokerCheck | A free lookup of registration and disclosure history before you sign an engagement letter |
Two or three written bids on the same EBITDA definition tell you more about your price than any published table. Once you have them, enter the lowest and highest written multiples as the calculator's low and high cases.
The 5-Line Bridge: From Adjusted EBITDA to Cash at Close
Enterprise value, equity value and cash at close are three different numbers. The bridge keeps them apart. Each line maps to a worksheet line further down.
- Adjusted EBITDA (worksheet line A) = reported EBITDA at the unadjusted margin, plus documented one-time costs from their own field, plus owner pay above market replacement pay for every owner (minus the shortfall if owners are underpaid), plus the rent adjustment (positive if owner rent is above market, negative if below).
- Enterprise value (line D) = adjusted EBITDA x the low and high multiples (line C).
- Equity value (line F) = EV minus net debt. The calculator stops here.
- Escrow (line G) = escrow rate x the base your purchase agreement names. SRS Acquiom reports escrow against "transaction value." Agreements apply the rate to purchase price, EV or equity value, and some carve out contingent consideration. Base rule: an EV base holds back more than an equity base by exactly the escrow rate times net debt. If your LOI does not name a base, ask, and model both until it does.
- Cash at close, before fees and taxes (line H) = equity value minus escrow, minus any price deferred into an earnout or rolled into buyer equity.
Sensitivity rule. Each turn of multiple moves enterprise value by one year of adjusted EBITDA. Cash at close moves by less, because escrow, earnout and rollover take their share of every added dollar. On $1.2 million of adjusted EBITDA, going from 5x to 6x adds $1.2 million of EV, and a $100,000 add-back rejected at 6x costs $600,000 of EV (our arithmetic). Document every add-back before you argue about the multiple.
Owner spending is where most add-backs come from. The owner's car, the office build-out and conference travel all sit inside reported EBITDA. Normalize them and back each one with invoices, because the buyer will test every line. The QoE prep checklist sets out the file.
Calculator Run: A Multi-Specialty Practice in FOCUS's $5 to $10 Million Band
Example (invented inputs): a multi-specialty practice has $30,000,000 of revenue and an 18% reported EBITDA margin, entered unadjusted. One-time costs are $0. Three owner physicians draw $2,100,000 in total, expensed in the P&L, against market pay of $500,000 each. Rent is at market, so the rent adjustment is $0. Net debt of $3,000,000 is repaid at closing.
How the multiples were set. Adjusted EBITDA of $6,000,000 sits in FOCUS's $5 to $10 million column, so FOCUS's published 8.8x is the high case. The low case, 7.0x, is our judgment, not a market figure. FOCUS says "density and ancillaries drive premium outcomes," and this practice has no in-house ancillaries, so the low case sits 1.8 turns under the FOCUS figure. The 8.8x already prices a business of this size, so the run adds nothing for the $10 million revenue line.
| Step | Input or formula | Low | High |
|---|---|---|---|
| Reported EBITDA | $30,000,000 x 18% | $5,400,000 | $5,400,000 |
| One-time costs | Input | $0 | $0 |
| Owner-pay add-back | $2,100,000 minus (3 x $500,000) | $600,000 | $600,000 |
| Adjusted EBITDA | Sum, a 20% margin | $6,000,000 | $6,000,000 |
| Multiple | Input | 7.0x (our judgment) | 8.8x (FOCUS 2026) |
| Enterprise value | $6,000,000 x multiple | $42,000,000 | $52,800,000 |
| Net debt | Input | $3,000,000 | $3,000,000 |
| Equity value | EV minus net debt | $39,000,000 | $49,800,000 |
| Escrow at 11.1%, EV base | 11.1% x EV | $4,662,000 | $5,860,800 |
| Cash at close, EV base | Equity value minus escrow | $34,338,000 | $43,939,200 |
| Escrow at 11.1%, equity base | 11.1% x equity value | $4,329,000 | $5,527,800 |
| Cash at close, equity base | Equity value minus escrow | $34,671,000 | $44,272,200 |
| Implied EV/revenue (hand check) | EV / $30,000,000 | 1.40x | 1.76x |
The 11.1% is SRS Acquiom's median total escrow for 2025 deals without RWI across all sectors, used here as an assumption. Cash at close is before fees, taxes, earnout and rollover. The EV base holds back $333,000 more than the equity base at both ends, which is 11.1% x $3,000,000 of net debt. That gap is 7.5 times the $44,400 gap in the dermatology example below, because this practice carries 7.5 times the net debt. The more net debt, the more the escrow base is worth negotiating.
2026 Multiples Tables: FOCUS Private Benchmarks and Damodaran Public Sectors
FOCUS Investment Banking, 2026 dashboard, private companies with $5M to $10M of EBITDA
| Sector | EV/EBITDA |
|---|---|
| Medical practices (multi-specialty) | 8.8x |
| Hospitals | 9.7x |
| Medical device | 10.4x |
| Plastic surgery | 11.3x |
| Medtech (software and digital health) | 14.4x |
Source: FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard. Each figure is a single published benchmark for that size band, not a closed-deal median with a stated sample.
The dermatology bands sit in their own table below because FOCUS sorts them by revenue, not EBITDA. Do not place a dermatology practice in the EBITDA table or a multi-specialty practice in the revenue table.
Damodaran, US listed companies, EV/EBITDA by sector, data as of January 2026
| Sector | Firms | EV/EBITDA |
|---|---|---|
| Hospitals/Healthcare Facilities | 31 | 8.86x |
| Healthcare Support Services | 104 | 11.17x |
| Drugs (Pharmaceutical) | 228 | 15.25x |
| Drugs (Biotechnology) | 496 | 15.78x |
| Healthcare Products | 204 | 19.78x |
| Healthcare Information and Technology | 115 | 21.27x |
| Total market excluding financials | 4,822 | 16.95x |
Source: Aswath Damodaran, NYU Stern, EV/EBITDA multiples by sector (US), January 2026. These are listed companies, traded daily and far larger than any practice. They are not private-practice prices.
Public company trading multiples. Private practices usually trade below these.
Chart data
| Healthcare IT | 21.27 |
|---|---|
| Healthcare products | 19.78 |
| Total market ex-financials | 16.95 |
| Biotechnology | 15.78 |
| Pharmaceutical | 15.25 |
| Healthcare support services | 11.17 |
| Hospitals and facilities | 8.86 |
Source: Aswath Damodaran, NYU Stern, EV/EBITDA by industry, January 2026
Three rules for reading the two tables:
- Do not read a private premium into mismatched rows. FOCUS's 9.7x for private hospitals is one figure for $5 to $10 million of EBITDA. Damodaran's 8.86x covers 31 listed hospital and facility companies, most far larger. The gap says nothing about private hospitals outpricing public ones.
- Do not average across sources. FOCUS's public healthcare services median of about 11.5x (below) and Damodaran's January 2026 figure of 11.17x for 104 listed Healthcare Support Services companies come from different company sets and dates. They sit close, but they do not measure the same thing.
- Do not price an operating practice on a software multiple. Damodaran's 21.27x for 115 listed Healthcare Information and Technology companies and FOCUS's 14.4x for medtech software describe software businesses. Owners adding AI scheduling or documentation tools should expect buyers to count the savings in EBITDA, not to reprice the practice as software.
Outer-bound check (our judgment, across different populations). A private buyer prices in illiquidity, key-person risk and payer concentration that a listed company does not carry. If your high multiple exceeds Damodaran's 11.17x for listed Healthcare Support Services companies and your practice is not at platform scale, write down why a buyer would pay more for it than investors pay for listed healthcare services companies. If you cannot, lower the high case. Scale is the exception. FOCUS's 12x to 15x for large dermatology platforms sits above 11.17x, which is why this check flags a high multiple instead of forbidding it.
Dermatology's 4 Size Bands: 3x to 15x EBITDA in 2026
Dermatology led 2025 outpatient deal counts with 24 of PESP's 148 outpatient transactions (Becker's ASC Review). FOCUS's 2026 benchmarks show how far a multiple moves within one specialty. Quoted descriptions are FOCUS's wording.
| Band (revenue) | EBITDA multiple | FOCUS description | What moves a practice up a band |
|---|---|---|---|
| Solo, under $2M | 3x to 5x | "Owner-dependent, limited geographic reach, physician-to-physician deals" | A second provider producing a meaningful share of collections |
| Small group, $2M to $15M | 4x to 7x | "Broader provider base, mix of medical and cosmetic services, growing buyer pool" | Centralized management and in-house ancillaries |
| Regional platform, $15M to $50M | 8x to 10x | "Centralized management, in-house pathology and/or Mohs, diversified payor base" | Multi-state presence and institutional systems |
| Large platform, $50M+ or $10M+ EBITDA | 12x to 15x | "Institutional infrastructure, multi-state presence, and scalable growth play" | Top band |
Source: FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks.
The bands overlap. Solo tops out at 5x and small group starts at 4x. The small-group band covers practices from $2 million to $15 million of revenue, so its top end is 7.5 times its bottom end (our arithmetic), all under one 4x to 7x multiple. Steady margins, diversified collections and more than 70% commercial or cash-pay revenue push toward the top. Lumpy cosmetic revenue or one dominant producer pushes toward the bottom.
Structure at the top. FOCUS reports that platform-ready dermatology practices, typically $5 million or more of EBITDA, get the highest valuations and the most favorable structures, often 70% or more cash at close with meaningful rollover equity. Below that size, plan for a smaller cash share and more escrow or earnout.
Decision rule. If one physician produces most of the collections and has no signed plan to stay after the sale, model the solo band first, whatever the revenue. Model the next band up as the upside case.
Worked Example: A Small Dermatology Group in 2026
Example (invented inputs): a dermatology group has $6,000,000 of revenue, placing it in FOCUS's $2 to $15 million band at 4x to 7x. Reported EBITDA is $900,000, a 15% margin, entered unadjusted. One-time costs are $0. The one owner takes $700,000 in expensed salary against a $450,000 market replacement salary, a $250,000 add-back. The practice pays the owner's real estate entity $50,000 a year above market rent, so the rent adjustment is entered as plus $50,000. Adjusted EBITDA is $900,000 + $250,000 + $50,000 = $1,200,000, a 20% margin. Net debt of $400,000 is paid off at closing.
| Bridge line | Low (4x) | High (7x) |
|---|---|---|
| Adjusted EBITDA | $1,200,000 | $1,200,000 |
| Enterprise value | $4,800,000 | $8,400,000 |
| Less net debt | $400,000 | $400,000 |
| Equity value (calculator output) | $4,400,000 | $8,000,000 |
| No RWI, 11.1% median escrow | ||
| Escrow on EV base | $532,800 | $932,400 |
| Cash at close, EV base | $3,867,200 | $7,067,600 |
| Escrow on equity base | $488,400 | $888,000 |
| Cash at close, equity base | $3,911,600 | $7,112,000 |
| With RWI, 2.8% median escrow | ||
| Escrow on EV base | $134,400 | $235,200 |
| Cash at close, EV base | $4,265,600 | $7,764,800 |
| Escrow on equity base | $123,200 | $224,000 |
| Cash at close, equity base | $4,276,800 | $7,776,000 |
The escrow rates are SRS Acquiom's medians for 2025 deals across all sectors, used as assumptions. A small practice deal can carry a different holdback. Cash at close is before fees and taxes, and the RWI rows are before the RWI premium. Without RWI, the EV base holds back $44,400 more than the equity base at both ends, exactly 11.1% of the $400,000 net debt. At the high end, RWI moves $697,200 (EV base) or $664,000 (equity base) from deferred cash to cash at close. Whether that trade pays depends on the premium quote.
Owner-dependence case. If buyers price the group in the solo band at 3x to 5x, EV falls to $3,600,000 to $6,000,000. The high end drops $2,400,000 (7x vs 5x) on the same EBITDA. That swing exceeds every escrow line in the table, and it is the clearest reason to add a second producing provider before a sale.
Rent case. The $50,000 rent adjustment assumes the buyer signs a new lease at market. If the owner keeps the building and the buyer takes over the current lease, the adjustment disappears and costs $200,000 to $350,000 of EV at 4x to 7x.
Cash-flow check. EBITDA excludes the lasers, devices and software the group must replace to keep producing. At $150,000 a year of replacements, cash flow before debt service, taxes and working capital is $1,050,000. The $8,400,000 high-end EV is then 8.0x that cash flow, and a buyer applying 7x to cash flow offers $7,350,000. Put three years of equipment spending next to your EBITDA. Check whether any "one-time" cost shows up in each prior year, because a buyer will treat a repeating cost as recurring and strike it from the one-time field.
Two Offers, One Practice: Comparing Price and Structure
Structure is how buyers bridge a price gap. The higher headline often carries more deferred and contingent money, so test every offer on cash at close and on what the earnout is worth to you. The Earnout Value Calculator handles the present-value step.
Assumptions for this example. Same dermatology group, $1,200,000 of adjusted EBITDA, $400,000 of net debt. Headline EV is the full price, including any earnout. Escrow rates are the SRS Acquiom 2025 all-sector medians (2.8% with RWI, 11.1% without). Escrow applies to headline EV, earnout included, unless a row says otherwise. Offer B's 20% earnout is an invented term. Fees, taxes and the RWI premium are excluded. All figures are our arithmetic.
| Line | Offer A: 5x, RWI, no earnout | Offer B: 6x, no RWI, 20% earnout |
|---|---|---|
| Headline EV (includes earnout) | $6,000,000 | $7,200,000 |
| Less net debt | $400,000 | $400,000 |
| Equity value (includes earnout) | $5,600,000 | $6,800,000 |
| Escrow (2.8% vs 11.1% of headline EV) | $168,000 | $799,200 |
| Earnout (20% of headline EV) | $0 | $1,440,000 |
| Cash at close | $5,432,000 | $4,560,800 |
Offer B's headline is $1,200,000 higher, but it pays $871,200 less at close. Three terms produce that gap, and they pull in different directions:
| Driver of the gap | Effect on Offer B's cash at close vs Offer A |
|---|---|
| Higher multiple (6x vs 5x on $1,200,000) | $1,200,000 more |
| No RWI: 11.1% vs 2.8% escrow on $7,200,000 | $597,600 less |
| Escrow on the extra $1,200,000 of headline at 2.8% | $33,600 less |
| Earnout (20% of $7,200,000 deferred) | $1,440,000 less |
| Net gap | $871,200 less |
The earnout alone moves $1,440,000 out of closing. The higher multiple wins back $1,200,000 of it, and the escrow difference takes $631,200. The escrow base changes the total. Bases that include the earnout overstate what Offer B holds back at closing, so the carve-out rows are the fairer test:
| Escrow base | Offer A escrow | Offer B escrow | Offer A cash at close | Offer B cash at close | Gap |
|---|---|---|---|---|---|
| Headline EV, earnout included | $168,000 | $799,200 | $5,432,000 | $4,560,800 | $871,200 |
| Equity value, earnout included | $156,800 | $754,800 | $5,443,200 | $4,605,200 | $838,000 |
| EV, earnout carved out (B: $5,760,000) | $168,000 | $639,360 | $5,432,000 | $4,720,640 | $711,360 |
| Equity value, earnout carved out (B: $5,360,000) | $156,800 | $594,960 | $5,443,200 | $4,765,040 | $678,160 |
Offer A wins at close on all four bases.
Earnout payout scenarios (undiscounted, assuming both escrows release in full with no claims). Offer A delivers $5,600,000. Offer B delivers $5,360,000 before any earnout.
| Share of the $1,440,000 earnout paid | Offer B total | Compared with Offer A's $5,600,000 |
|---|---|---|
| 0% | $5,360,000 | $240,000 less |
| About 16.7% ($240,000) | $5,600,000 | Break-even |
| 50% | $6,080,000 | $480,000 more |
| 100% | $6,800,000 | $1,200,000 more |
Escrow-claim scenario (headline EV base, assuming each buyer recovers half its escrow through claims). Offer A falls $84,000 to $5,516,000. Offer B's pre-earnout total falls $399,600 to $4,960,400. Offer B then needs $555,600 of earnout, about 38.6% of it, to break even. The bigger the escrow, the more a claim moves the comparison.
None of these figures discount for time or account for who controls the business during the earnout. Those two factors decide how reachable a payout share is. Get both offers in writing on the same base, ask the higher bidder for a version with less structure at its own price, and choose on cash at close plus the payout share you would bet on.
Escrow in 2025 Deals: SRS Acquiom's Data
| Escrow measure, 2025 deals, all sectors | Average | Median |
|---|---|---|
| General indemnification escrow, no RWI | 11.3% | 10.0% |
| General indemnification escrow, with RWI | 2.2% | 0.5% |
| Total escrow, no RWI | 14.7% | 11.1% |
| Total escrow, with RWI | 5.1% | 2.8% |
Source: SRS Acquiom, 2026 Deal Terms for M&A Escrows, 2025 deals in SRS Acquiom's M&A dataset, as a percentage of transaction value.
RWI shrinks the escrow but rarely removes it. In the same 2025 data, 92% of deals with RWI still carried an indemnification escrow or holdback, against 84% of deals without RWI. In every row the average sits above the median, so a tail of large holdbacks pulls the average up. Benchmark a proposed escrow against the median.
Ask the buyer before you accept a headline number:
- What base does the escrow apply to (purchase price, EV or equity value), and does it include contingent consideration?
- When does the escrow release, and in how many installments?
- Will the buyer use RWI, and who pays the premium and retention?
- What share of the price sits in an earnout, on what metric, over what period, and when does measurement start?
- During the earnout, who controls hiring, payer contracting, pricing and billing?
- If part of the price is rollover equity, what are the transfer limits and when can it be sold?
The LOI and term sheet red flags checklist covers the drafting traps, and the healthcare deal structures guide covers earnout and rollover mechanics.
The Public Median Fell From 14.5x to 11.5x: What It Means for Private Bids
FOCUS's 2026 dashboard reports that the median EV/EBITDA multiple for publicly traded healthcare services companies "declined to approximately 11.5x in 2026, down from 14.5x the prior year." That is a drop of 3 turns, or about 20.7% (our arithmetic, on FOCUS's rounded figures).
FOCUS reports three other public figures, each on a different measure, population or date. Read each on its own:
| FOCUS figure | Population and date | Value |
|---|---|---|
| Median EV/EBITDA, public healthcare services | FOCUS's public set, as reported in its 2026 dashboard | About 11.5x, down from 14.5x the prior year |
| Median TEV/EBITDA, public healthcare operators | Public comps, Q2 2025 | 12.4x |
| Share of EV growth from multiple expansion | Public healthcare operators, Q2 2025 | About 68% |
| Operators with higher implied forward multiples | Public operators, July to August 2025 | 13 of 16 |
What it means for a seller:
- Less room for a private premium. PE-backed platforms that plan to exit to larger acquirers price off public comparables. A lower public median compresses what they can pay and still earn their return.
- Earnings hold value better than pricing. FOCUS attributes about 68% of Q2 2025 EV growth among public operators to multiple expansion rather than EBITDA growth. That figure covers a different set and period than the 11.5x median and does not explain the decline. It does show how much of the earlier gain rested on pricing. In a private sale, EBITDA you can document holds its value better than a multiple you were quoted.
- Demand is still growing. CMS reports that physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024 and projects 5.5% average annual growth for 2025 to 2034 (CMS NHE fact sheet). Volume growth supports EBITDA even when buyers pay fewer turns for it, which is one more reason to build value through earnings.
- Stale anchors. A colleague's sale from last year may sit at a level the public market no longer supports. Ask anyone quoting you a multiple for its date and sample, and how much was paid at close and how much sat in escrow or an earnout.
Copy-Ready Worksheet: 8 Lines, Each With Its Formula and Source
Copy this into a spreadsheet. Fill column 2 from your records and each written offer. Column 4 is what you cite when a buyer asks where a number came from. The letters match the bridge above and the diligence table below.
| Line | Your figure | Formula | Benchmark to cite, with date |
|---|---|---|---|
| A. Adjusted EBITDA | Reported EBITDA at the unadjusted margin + one-time costs (own field) + owner-pay add-back + rent adjustment (plus if above market, minus if below) | Your add-back file | |
| B. Annual equipment and software replacement | Three-year average from your books | Your records | |
| C. Low and high multiple | Size first, then specialty, owner dependence, payer mix and buyer type | FOCUS 2026 dashboard or FOCUS dermatology 2026, or a buyer's written quote | |
| D. Enterprise value | A x C | Calculator output | |
| E. Cash-flow multiple implied | D / (A minus B) | Cash-flow check above | |
| F. Equity value | D minus net debt | Calculator output | |
| G. Escrow | Rate x the base in the LOI (run EV and equity bases if unstated, with and without contingent consideration) | SRS Acquiom 2026 escrow report, 2025 deals, all sectors | |
| H. Cash at close before fees and taxes | F minus G minus earnout minus rollover | Carry to the Deal Proceeds Calculator |
Keep earnout and rollover in their own rows. Treat the earnout as undiscounted scenario math and carry rollover at cost with no cash at close.
What Buyers Verify: 7 Items and Why Each Moves the Multiple
A buyer applies its multiple only to EBITDA it can verify. Each gap lands on a worksheet line. The full request list is in the buyer due diligence checklist.
| Item to prepare | Red flag if missing | Worksheet line it hits |
|---|---|---|
| Financials, ideally reviewed or audited, with monthly detail that ties to tax returns | Buyer cannot confirm reported EBITDA | Line C (lower multiple) and line G (larger escrow) |
| Add-back file with payroll records, leases and invoices | Undocumented add-backs get rejected | Line A, multiplied by the full multiple |
| Three years of equipment and software spending | Buyer prices on cash flow instead of EBITDA | Line B, as in the cash-flow check above |
| Revenue by payer, with renewal dates | A large contract near renewal is a future-EBITDA risk, and a government-heavy mix forfeits the commercial-pay preference | Line C, or an earnout that reduces line H |
| Collections by provider | Concentration in the owner points to the solo band | Line C, as in the $2,400,000 owner-dependence case above |
| Ancillary revenue (pathology, imaging, Mohs) shown separately | Buyer cannot credit what FOCUS calls premium drivers | Line C |
| Compliance file | Referral or ownership problems surface in diligence | Line G (special indemnity or escrow), or a failed deal |
Seller preparation order (our recommendation). Fix the items that hit line A first, because every rejected dollar is lost at the full multiple. Then build the provider and payer reports that support line C. Escrow and structure terms come last, once a buyer has accepted your EBITDA.
Before You Sign an LOI: Seven Terms Ranked by Their Swing in the Dermatology Example
An LOI fixes most of the numbers that decide cash at close. The table ranks the terms by the dollar swing each one produced in the dermatology group above ($1,200,000 of adjusted EBITDA, $400,000 of net debt). Settle the largest ones in writing before you sign. All figures are our arithmetic from the dermatology examples on this page.
| Term to pin down | Question to settle in the LOI | Swing in the dermatology example | Where it is worked |
|---|---|---|---|
| Size band and owner dependence | Which band is the buyer pricing, and what retention plan supports it? | $2,400,000 of EV at the high end (7x vs 5x) | Owner-dependence case |
| Earnout share | How much of the headline sits in an earnout, on what metric? | $1,440,000 of Offer B's price moved from closing into contingent pay | Gap breakdown in the two-offer section |
| Cash-flow vs EBITDA pricing | Is the multiple applied to EBITDA or to EBITDA after equipment spending? | $1,050,000 of EV ($8,400,000 vs $7,350,000) | Cash-flow check |
| RWI | Will the buyer use RWI, and who pays the premium? | $697,200 moved to cash at close at 7x (EV base) | Worked example table |
| Each accepted add-back | Which add-backs does the buyer accept, stated as a separate EBITDA figure? | $600,000 of EV per $100,000 rejected at 6x | Sensitivity rule |
| Rent treatment | Will the buyer sign a new lease at market or keep the current one? | $200,000 to $350,000 of EV | Rent case |
| Escrow base | Does escrow apply to EV or equity value, with or without the earnout? | $44,400 at 11.1% (EV vs equity base) | Worked example table |
How to use it. Run the calculator once for each written bid, then fill a column per bid with that buyer's answer to each question. A bid that leaves the top three rows open is not yet comparable to one that answers them. The sale readiness guide sets the order of work in the months before bids arrive.
The Seven LOI Terms Scored for Offer A and Offer B
Here is the scorecard filled in for the two offers above, using only figures already on this page. Each "exposure" cell shows what the term could cost that offer if the buyer's position moves against you. All figures are our arithmetic.
| Term | Offer A: 5x, RWI, no earnout | Offer B: 6x, no RWI, 20% earnout | Exposure, A vs B |
|---|---|---|---|
| Size band and owner dependence | 5x, the top of the solo band and inside the small-group band | 6x, above the solo band's 5x ceiling | A: none if repriced to the solo top. B: $1,200,000 of EV if repriced to 5x |
| Earnout share | $0 | $1,440,000 deferred | B only: the full $1,440,000 depends on the metric and on who runs the business |
| Cash-flow vs EBITDA pricing | Priced on EBITDA | Priced on EBITDA | If either buyer moves to $1,050,000 of cash flow: A loses $750,000 of EV, B loses $900,000 |
| RWI | Yes, 2.8% escrow, $168,000 | No, 11.1% escrow, $799,200 | B holds back $631,200 more |
| Each accepted add-back | $500,000 of EV per $100,000 rejected | $600,000 of EV per $100,000 rejected | Every rejected add-back costs B one-fifth more |
| Rent treatment | $50,000 adjustment worth $250,000 of EV | $50,000 adjustment worth $300,000 of EV | Both lose it if the current lease carries over |
| Escrow base | $11,200 gap between EV and equity base | $44,400 gap between EV and equity base, and $159,840 more if the earnout is not carved out of the EV base | B gains more from negotiating the base |
| Cash at close, headline EV base | $5,432,000 | $4,560,800 | A leads by $871,200 |
Reading the scorecard. Offer B's higher multiple raises its exposure on every row that scales with the multiple (add-backs, rent, cash-flow pricing), and it carries the only earnout. Before treating B as the better offer, ask its buyer to confirm in writing which add-backs it accepts, whether it prices on EBITDA, and what retention plan supports a 6x multiple. If those three answers come back favorable and you would bet on at least the 16.7% break-even payout, B can still come out ahead over time. Otherwise A is the stronger bid.
Post-closing physician pay, rollover equity and any management services structure raise questions covered in the healthcare compliance due diligence guide and the management services organizations guide, and deal size or location can bring in reviews covered in the healthcare M&A process guide. Take the questions those pages raise to your own attorney before the LOI fixes the structure, because the answers can change the structure or the timetable.
Who Buys Practices Now: Platforms, Hospitals and Other Physicians
Chart data
| Private practice (physician-owned) | 42.2 |
|---|---|
| Hospital-owned practice | 34.5 |
| Directly employed by hospital | 12.2 |
| Private equity-owned practice | 6.5 |
Source: American Medical Association, Physician Practice Benchmark Survey 2024
The chart shows physician employment by practice ownership from the AMA's 2024 Physician Practice Benchmark Survey. It counts where physicians work, not bids or multiples. The deal data below shows who is buying.
| Buyer group | 2025 and 2026 activity | Source |
|---|---|---|
| PE-backed outpatient platforms | 148 outpatient care deals in 2025, 119 of them add-ons | PESP 2025 data via Becker's ASC Review |
| Hospital acquirers | 22 transactions announced in Q1 2026, 18 in Q2 and 16 in Q3, for 56 through Q3 against 46 in all of 2025 | Kaufman Hall data via Becker's Hospital Review |
Kaufman Hall's 46 transactions in 2025 were its lowest annual count since it began tracking hospital transactions in 2011. Its counts cover hospital transactions, not physician practice purchases. They show hospital systems doing more deals in 2026, not more practice bids. Each buyer group prices owner dependence, payer mix and earnout risk differently. Model at least two of them, as in the two-offer table, and compare cash at close, not headline value.
| Buyer type | What it typically weighs most | How to model it here |
|---|---|---|
| PE-backed platform adding a location | Documented EBITDA, payer mix, provider retention | Sponsor case at your band, with escrow and rollover lines |
| Strategic or corporate buyer | Fit with its services and technology | Sponsor multiple x 1.2 to 1.4, only if one is bidding (FOCUS 2026 sector premium, applied to practices as our assumption) |
| Hospital system | Referral base and market position | Separate case, with post-closing physician pay set at market |
| Physician buyer or partner buy-in | Owner's production and transition | Solo or small-group band, with more seller financing and no rollover. The SBA 7(a) program sets a loan limit that can change, which limits what one physician buyer can finance through it. Confirm the current limit with the lender. |
Worked example, physician buyer (our arithmetic, invented inputs). A solo practice with $600,000 of adjusted EBITDA at 4x has an EV of $2,400,000. A small group with $1,200,000 at 5x has an EV of $6,000,000. Confirm the current 7(a) loan limit with the lender. If the price exceeds it, the buyer needs the difference from seller financing, its own equity or other lenders. If your realistic buyer is another physician, size that gap before you set your price expectation.
Questions Practice Owners and Investors Ask
What multiple of EBITDA does a medical practice sell for in 2026?
FOCUS Investment Banking's 2026 dashboard gives 8.8x for multi-specialty medical practices with $5 to $10 million of EBITDA. That is a single published benchmark figure, not a closed-deal median. Smaller practices sell for less. FOCUS's 2026 dermatology benchmarks price small groups with $2 to $15 million of revenue at 4x to 7x and solo practices under $2 million of revenue at 3x to 5x. Place your practice by size first, then adjust for specialty, owner dependence, payer mix and buyer type.
How much is a dermatology practice worth?
Multiply adjusted EBITDA by the FOCUS 2026 band that fits. Solo practices under $2 million of revenue trade at 3x to 5x. Small groups with $2 to $15 million trade at 4x to 7x. Regional platforms with $15 to $50 million trade at 8x to 10x, and platforms with $50 million or more of revenue or $10 million or more of EBITDA trade at 12x to 15x. Example (our arithmetic): $1.2 million of adjusted EBITDA at small-group multiples gives $4.8 to $8.4 million of enterprise value, before net debt, escrow, fees and taxes.
Do strategic buyers pay more than private equity for a healthcare business?
FOCUS Investment Banking's 2026 dashboard found that corporate buyers in therapeutic and technology-driven sectors paid 20% to 40% higher multiples than financial sponsors on a like-for-like EBITDA basis. FOCUS measured that for those sectors, not for physician practices, so apply it to a practice only when a strategic buyer is actually bidding. Private equity competes on structure as well as price. FOCUS reports that platform-ready dermatology practices, typically $5 million or more of EBITDA, often receive 70% or more of the price in cash at close plus meaningful rollover equity.
How much of the sale price is held back in escrow when I sell my practice?
SRS Acquiom's 2026 Deal Terms for M&A Escrows covers 2025 deals across its M&A dataset in all sectors, not practice sales alone. Deals without reps and warranties insurance (RWI) had a median total escrow of 11.1% of transaction value. Deals with RWI had a median of 2.8%. Escrow is deferred cash, released later if no claims are made. Your purchase agreement sets the rate, the base it applies to and the release dates.
Does crossing $10 million of revenue raise my multiple?
FOCUS reports that companies above $10 million of annual revenue often see a 1.5x to 2x jump in valuation multiples, as buyers price in infrastructure maturity and margin consistency. The figure covers healthcare companies generally, not one specialty. FOCUS does not say whether the jump multiplies the multiple or adds turns. On a 4x starting multiple, a multiplier reading gives 6x to 8x and a turns reading gives 5.5x to 6x (our arithmetic). Treat it as a direction, not a step at an exact revenue line.
Where do one-time costs go in the calculator?
In the one-time costs field only. Enter your reported EBITDA margin exactly as your financial statements show it, with no adjustment, and enter each documented one-time cost in its own field. If you also raise the margin to strip those costs out, you count them twice and overstate value by the cost times the multiple.
Can a physician buyer use an SBA loan to buy my practice?
Yes, if the buyer qualifies. The SBA's 7(a) program is its main small business loan program, and the program sets a loan limit that can change, so confirm the current limit with the lender. That limit restricts how much of a price a single physician buyer can finance through 7(a), so physician-to-physician deals at larger sizes usually add seller financing or buyer equity.
Sources
- FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard (2026, with public figures for Q2 2025 and July to August 2025)
- FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks (2026)
- Aswath Damodaran, NYU Stern, EV/EBITDA Multiples by Sector (US) (data as of January 2026)
- SRS Acquiom, 2026 Deal Terms for M&A Escrows (2025 deal data, all sectors)
- CMS, National Health Expenditure Fact Sheet (2024 spending, 2025 to 2034 projections)
- U.S. Small Business Administration, 7(a) Loans
- U.S. Bureau of Labor Statistics, Health Care and Social Assistance (current employment and wage data)
- FINRA BrokerCheck
- Becker's ASC Review, The outpatient specialties that dominated 2025 deal activity (PESP 2025 data)
- Becker's Hospital Review, Hospital M&A on pace for busiest year since pandemic (Kaufman Hall data through Q3 2026)
- American Medical Association, press release on the 2024 Physician Practice Benchmark Survey (2024 survey, chart data)